These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 2467946)

  • 1. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.
    Ellis TM; Fisher RI
    J Immunol; 1989 Apr; 142(8):2949-54. PubMed ID: 2467946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
    Ferrini S; Miescher S; Zocchi MR; von Fliedner V; Moretta A
    J Immunol; 1987 Feb; 138(4):1297-302. PubMed ID: 3100633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB; Itoh K; Balch CM
    J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
    McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
    J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
    Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
    Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
    Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
    J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.
    Ellis TM; Creekmore SP; McMannis JD; Braun DP; Harris JA; Fisher RI
    Cancer Res; 1988 Nov; 48(22):6597-602. PubMed ID: 2902918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody.
    Yun YS; Hargrove ME; Ting CC
    J Immunol; 1988 Aug; 141(4):1390-7. PubMed ID: 3260924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations.
    Ballas ZK; Rasmussen W
    J Immunol; 1990 Jan; 144(1):386-95. PubMed ID: 2104892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.